<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Multiparameter immunophenotypic analysis of neoplastic cells has proven to be of great help for the investigation of <z:e sem="disease" ids="C0242596" disease_type="Neoplastic Process" abbrv="MRD">minimal residual disease</z:e> in <z:hpo ids='HP_0002488'>acute leukemias</z:hpo>; however, its utility has not been systematically explored in B cell <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of the present study was to investigate the incidence of phenotypic aberrations in a series of 467 consecutive leukemic B cell <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> through the comparison of the phenotypic characteristics of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> vs <z:mpath ids='MPATH_458'>normal</z:mpath> peripheral blood (n = 10) and bone marrow (n = 10) B cells, in order to explore the applicability of this strategy for <z:e sem="disease" ids="C0242596" disease_type="Neoplastic Process" abbrv="MRD">minimal residual disease</z:e> monitoring </plain></SENT>
<SENT sid="2" pm="."><plain>An additional goal of our study was to evaluate the sensitivity of multiparameter flow cytometry for the detection of <z:e sem="disease" ids="C0242596" disease_type="Neoplastic Process" abbrv="MRD">minimal residual disease</z:e> in leukemic B cell <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> through dilutional experiments (n = 19) </plain></SENT>
<SENT sid="3" pm="."><plain>From the patients analyzed 382 corresponded to B cell <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo>/small lymphocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (353 typical and 29 atypical); five to prolymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo>; 13 to hairy cell <z:hpo ids='HP_0001909'>leukemias</z:hpo>; 12 to lymphoplasmacytic <z:hpo ids='HP_0002665'>lymphomas</z:hpo>; 14 to splenic marginal zone <z:hpo ids='HP_0002665'>lymphomas</z:hpo>; 22 were follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo>; and 19 mantle cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>The following triple stainings were systematically applied to both <z:mpath ids='MPATH_458'>normal</z:mpath> and leukemic samples: FMC7/CD5/CD19, CD22/CD23/CD19, CD103/CD25/CD19, CD10/CD11c/CD19 and sIg/sIg(lambda)/CD19 </plain></SENT>
<SENT sid="5" pm="."><plain>Overall, 98% of the leukemic B cell <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> cases displayed aberrant phenotypes at diagnosis with no significant differences being found between cases analyzed in peripheral blood vs bone marrow samples </plain></SENT>
<SENT sid="6" pm="."><plain>The most common types of aberrant criteria detected included asynchronous antigen expression (92%) and antigen over-expression (54%); abnormally light scatter characteristics were found in 17% of the cases </plain></SENT>
<SENT sid="7" pm="."><plain>Most of the cases studied (90%) displayed four or more phenotypic aberrations </plain></SENT>
<SENT sid="8" pm="."><plain>Once patients were divided according to the different diagnostic subgroups, the overall incidence of aberrant phenotypes ranged from 79 to 80% among atypical B cell <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo>/small lymphocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and prolymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> to 97% of follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and 100% of typical B cell <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo>/small lymphocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, hairy cell <z:hpo ids='HP_0001909'>leukemia</z:hpo>, lymphoplasmacytic <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, splenic marginal zone <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and mantle cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Based on the aberrant phenotypes detected unique four-color stainings could be built for the specific identification of aberrant phenotypes </plain></SENT>
<SENT sid="10" pm="."><plain>These include CD22/CD23/CD19/CD5 and sIg(kappa)/sIg(lambda)/CD19/CD5 for lymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo>/small lymphocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and prolymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo>, CD103/CD25 or CD22/CD19/CD11c for hairy cell <z:hpo ids='HP_0001909'>leukemia</z:hpo>, FMC7/CD22/CD19/CD103 and sIg(kappa)/sIg(lambda)/CD22/CD19 for splenic marginal zone <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, CD22/CD23/CD19/CD10 for follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and CD10/CD22/CD19/CD5 for mantle cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>Serial dilutional experiments showed that the sensitivity level of immunophenotyping ranges between 10(-4) and 10(-5) </plain></SENT>
<SENT sid="12" pm="."><plain>In summary, the present study shows that immunophenotypic analysis allows the identification of aberrant phenotypes in 98% of leukemic B cell <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> and these phenotypes can be used for <z:e sem="disease" ids="C0242596" disease_type="Neoplastic Process" abbrv="MRD">minimal residual disease</z:e> monitoring with a sensitivity limit of 10(-4)-10(-5) </plain></SENT>
</text></document>